[1]
|
Gonzalez, R.S. (2020) Diagnosis and Management of Gastrointestinal Neuroendocrine Neoplasms. Surgical Pathology Clinics, 13, 377-397. https://doi.org/10.1016/j.path.2020.04.002
|
[2]
|
李晓玲, 等. 177例胃肠神经内分泌肿瘤的临床病理分析[J]. 广东医科大学学报, 2021, 39(3): 357-360.
|
[3]
|
Dasari, A., et al. (2017) Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncology, 3, 1335-1342. https://doi.org/10.1001/jamaoncol.2017.0589
|
[4]
|
Pavel, M., et al. (2020) Gastroenteropancreatic Neuroendocrine Neoplasms: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 31, 844-860. https://doi.org/10.1016/j.annonc.2020.03.304
|
[5]
|
WHO Classification of Tumours Edito-rial Board (2019) WHO Classification of Tumors: Digestive System Tumours. 5th Edition, International Agency for Re-search on Cancer, Lyon.
|
[6]
|
李远良, 罗杰, 谭煌英. 胃神经内分泌肿瘤的分型诊治进展[J]. 临床肿瘤学杂志, 2020, 25(9): 857-861.
|
[7]
|
胃肠胰神经内分泌肿瘤诊治专家共识(2020广州) [J]. 中华消化杂志, 2021, 41(2): 76-87.
|
[8]
|
熊羽佳, 等. 胃神经内分泌肿瘤148例临床病理特征和预后分析[J]. 中华消化杂志, 2020, 40(6): 407-410.
|
[9]
|
Tsai, H.J., et al. (2013) The Epidemiology of Neuroendocrine Tumors in Taiwan: A Nation-Wide Cancer Registry-Based Study. PLoS ONE, 8, e62487. https://doi.org/10.1371/journal.pone.0062487
|
[10]
|
Yao, J.C., et al. (2008) One Hundred Years after “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. Journal of Clinical Oncology, 26, 3063-3072.
https://doi.org/10.1200/JCO.2007.15.4377
|
[11]
|
中国临床肿瘤学会指南工作委员会. CSCO神经内分泌肿瘤诊疗指南[M]. 北京: 人民卫生出版社, 2021.
|
[12]
|
梁文全, 等. 104例胃神经内分泌肿瘤的临床病理特征及预后分析[J]. 中华胃肠外科杂志, 2016, 19(4): 427-431.
|
[13]
|
梁文全, 等. 240例胃神经内分泌肿瘤的临床病理特征及预后分析[J]. 中华胃肠外科杂志, 2020(1): 38-43.
|
[14]
|
熊羽佳, 等. 原发性胃神经内分泌肿瘤的临床特点、病理及预后分析[J]. 中华内科杂志, 2020(4): 297-302.
|
[15]
|
王超, 等. 117例胃神经内分泌肿瘤的临床病理特征和预后分析[J]. 中国肿瘤临床, 2019, 46(5): 239-246.
|
[16]
|
孙大川, 等. 胃混合性神经内分泌-非神经内分泌肿瘤的临床病理特征和预后分析[J]. 中国医刊, 2021, 56(6): 651-654.
|
[17]
|
Basturk, O., et al. (2015) The High-Grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms. The American Journal of Surgical Pathology, 39, 683-690. https://doi.org/10.1097/PAS.0000000000000408
|
[18]
|
Tang, L.H., et al. (2016) Well-Differentiated Neuroendo-crine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clinical Cancer Research, 22, 1011-1017. https://doi.org/10.1158/1078-0432.CCR-15-0548
|
[19]
|
中国胃肠胰神经内分泌肿瘤病理诊断共识(2020版) [J]. 中华病理学杂志, 2021, 50(1): 14-20.
|
[20]
|
黄丹, 等. 胃肠胰高增殖活性神经内分泌肿瘤60例临床病理学特征和预后分析[J]. 中华病理学杂志, 2020(1): 12-13-14-15-16.
|
[21]
|
Busico, A., et al. (2020) Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin. Neuroendo-crinology, 110, 616-629. https://doi.org/10.1159/000503722
|
[22]
|
樊知遥, 等. 胃肠胰G3级神经内分泌瘤的诊治进展[J]. 中华外科杂志, 2021, 59(8): 704-710.
|
[23]
|
高鹤丽, 徐近, 虞先濬. 分化好的胃肠胰神经内分泌瘤G3的诊治新进展[J]. 中国癌症杂志, 2021, 31(7): 567-573.
|
[24]
|
Shamir, E.R., et al. (2019) Identification of High-Risk Human Papillomavirus and Rb/E2F Pathway Genomic Alterations in Mutually Exclusive Subsets of Colorectal Neuro-endocrine Carcinoma. Modern Pathology, 32, 290-305.
https://doi.org/10.1038/s41379-018-0131-6
|
[25]
|
Bellizzi, A.M. (2020) Immunohistochemistry in the Diagnosis and Classification of Neuroendocrine Neoplasms: What Can Brown Do for You? Human Pathology, 96, 8-33. https://doi.org/10.1016/j.humpath.2019.12.002
|
[26]
|
周越, 等. 胃肠胰神经内分泌肿瘤中Ki-67的表达及其预后的相关性研究[J]. 临床肿瘤学杂志, 2013, 18(6): 506-510.
|
[27]
|
Oberg, K. (2010) Neuroendocrine Tumors (NETs): Historical Overview and Epidemiology. Tumori, 96, 797-801.
https://doi.org/10.1177/030089161009600530
|
[28]
|
涂轶, 等. 基于Ki-67增殖指数判定的数字化分析在胃肠胰神经内分泌肿瘤分级中的应用[J]. 临床与实验病理学杂志, 2021, 37(7): 875-877.
|
[29]
|
Cao, Z., et al. (2021) Ex-pression of CD200 and INSM1 in Gastrointestinal and Pancreatic Neuroendocrine Neoplasms and Its Diagnostic Values. Chinese Journal of Pathology, 50, 1134-1138.
|
[30]
|
郭茹菲, 等. 胃神经内分泌肿瘤的病理学特征及临床意义[J]. 河南医学研究, 2021, 30(14): 2525-2529.
|
[31]
|
Kyriakopoulos, G., et al. (2018) Histopathological, Immunohistochemi-cal, Genetic and Molecular Markers of Neuroendocrine Neoplasms. Annals of Translational Medicine, 6, 252. https://doi.org/10.21037/atm.2018.06.27
|
[32]
|
Marotta, V., et al. (2018) Chromogranin A as Circulating Marker for Diagnosis and Management of Neuroendocrine Neoplasms: More Flaws than Fame. Endocrine-Related Cancer, 25, R11-R29. https://doi.org/10.1530/ERC-17-0269
|
[33]
|
Terlević, R., et al. (2019) Somatostatin Receptor SSTR2A and SSTR5 Expression in Neuroendocrine Breast Cancer. Annals of Diagnostic Pathology, 38, 62-66. https://doi.org/10.1016/j.anndiagpath.2018.11.002
|
[34]
|
Popa, O., et al. (2021) The New WHO Classification of Gastrointestinal Neuroendocrine Tumors and Immunohistochemical Expression of Somatostatin Receptor 2 and 5. Ex-perimental and Therapeutic Medicine, 22, 1179.
https://doi.org/10.3892/etm.2021.10613
|
[35]
|
Nielsen, K., et al. (2020) P53, Somatostatin Receptor 2a and Chro-mogranin A Immunostaining as Prognostic Markers in High Grade Gastroenteropancreatic Neuroendocrine Neoplasms. BMC Cancer, 20, Article No. 27.
https://doi.org/10.1186/s12885-019-6498-z
|
[36]
|
Konukiewitz, B., et al. (2017) Somatostatin Receptor Expression Related to TP53 and RB1 Alterations in Pancreatic and Extrapancreatic Neuroendocrine neoplasms with a Ki67-Index above 20. Modern Pathology, 30, 587-598.
https://doi.org/10.1038/modpathol.2016.217
|
[37]
|
Sorbye, H., Baudin, E. and Perren, A. (2018) The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroen-docrine Carcinomas, and Beyond. Endocrinology & Metabolism Clinics of North America, 47, 683-698. https://doi.org/10.1016/j.ecl.2018.05.001
|
[38]
|
Kaemmerer, D., et al. (2015) Inverse Expression of Somatostatin and CXCR4 Chemokine Receptors in Gastroenteropancreatic Neuroendocrine Neoplasms of Different Malignancy. Onco-target, 6, 27566-27579.
https://doi.org/10.18632/oncotarget.4491
|
[39]
|
Binderup, T., et al. (2010) Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET. Journal of Nuclear Medicine, 51, 704-712.
https://doi.org/10.2967/jnumed.109.069765
|
[40]
|
Brunner, P., et al. (2017) The Prognostic and Predictive Value of sstr(2)-Immunohistochemistry and sstr(2)-Targeted Imaging in Neuroendocrine Tumors. European Journal of Nuclear Medicine and Molecular Imaging, 44, 468-475.
https://doi.org/10.1007/s00259-016-3486-2
|
[41]
|
Sharma, S., et al. (2009) Role of MGMT in Tumor Development, Progression, Diagnosis, Treatment and Prognosis. Anticancer Research, 29, 3759-3768.
|
[42]
|
Yang, Q.C., et al. (2014) Expression of O(6)-methylguanine DNA Methyltransferase (MGMT) and Its Clinical Significance in Gastroentero-pancreatic Neuroendocrine Neoplasm. International Journal of Clinical and Experimental Pathology, 7, 4204-4212.
|
[43]
|
Christmann, M., Verbeek, B., Roos, W.P. and Kaina, B. (2011) O(6)-Methylguanine-DNA methyl-transferase (MGMT) in Normal Tissues and Tumors: Enzyme Activity, Promoter Methylation and Immunohistochemis-try. Biochimica et Biophysica Acta, 1816, 179-190. https://doi.org/10.1016/j.bbcan.2011.06.002
|
[44]
|
Ekeblad, S., et al. (2007) Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors. Clinical Cancer Research, 13, 2986-2991. https://doi.org/10.1158/1078-0432.CCR-06-2053
|
[45]
|
Welin, S., et al. (2011) Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma after Pro-gression on First-Line Chemotherapy. Cancer, 117, 4617-4622. https://doi.org/10.1002/cncr.26124
|
[46]
|
王玮, 周志伟. 胃神经内分泌肿瘤的外科治疗[J]. 中华胃肠外科杂志, 2021, 24(10): 849-853.
|
[47]
|
Delle, F.G., et al. (2016) ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology, 103, 119-124. https://doi.org/10.1159/000443168
|
[48]
|
Shah, M.H., et al. (2021) Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Net-work, 19, 839-868.
https://doi.org/10.6004/jnccn.2021.0032
|
[49]
|
陈洛海, 陈洁. 胃肠胰神经内分泌肿瘤诊治最新国际指南解读[J]. 中华胃肠外科杂志, 2021, 24(10): 843-848.
|
[50]
|
Xu, J., et al. (2019) Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial. Clinical Cancer Research, 25, 3486-3494.
https://doi.org/10.1158/1078-0432.CCR-18-2994
|
[51]
|
Spada, F.A.L.M. (2015) Chemotherapy with Capecitabine plus Temozolomide (CAP-TEM) in Patients with Advanced Neuroendocrine Neoplasms (NENs): An Italian Multicenter Retrospective Analysis. Neuroendocrinology: International Journal for Basic and Clinical Studies on Neuroendocrine Relationships, 102, 121.
|